Scarica l'app Stockscreener
10.00
2.99%
0.29
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ATRA Giù?
Forum
Previsione
Precedente Chiudi:
$9.71
Aprire:
$9.8
Volume 24 ore:
112.20K
Relative Volume:
2.06
Capitalizzazione di mercato:
$59.61M
Reddito:
$100.44M
Utile/perdita netta:
$-133.16M
Rapporto P/E:
-0.3882
EPS:
-25.76
Flusso di cassa netto:
$-94.85M
1 W Prestazione:
+8.34%
1M Prestazione:
+24.69%
6M Prestazione:
+52.21%
1 anno Prestazione:
-4.81%
Intervallo 1D:
$9.7764
$10.99
Intervallo di 1 settimana:
$8.53
$10.99
Portata 52W:
$5.005
$18.70
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Nome
Atara Biotherapeutics Inc
Settore
Industria
Telefono
805-623-4211
Indirizzo
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Confronta ATRA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
10.00 | 55.02M | 100.44M | -133.16M | -94.85M | -25.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-11-09 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-11-09 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | Downgrade | Mizuho | Buy → Neutral |
| 2022-07-20 | Downgrade | Citigroup | Neutral → Sell |
| 2022-07-13 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-07-13 | Downgrade | Stifel | Buy → Hold |
| 2022-05-10 | Downgrade | Citigroup | Buy → Neutral |
| 2021-05-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-12-09 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-10 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-30 | Iniziato | Evercore ISI | Outperform |
| 2020-06-15 | Iniziato | H.C. Wainwright | Buy |
| 2020-04-23 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-11-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-09-27 | Downgrade | Goldman | Neutral → Sell |
| 2019-09-16 | Downgrade | Jefferies | Buy → Hold |
| 2019-06-04 | Aggiornamento | Citigroup | Sell → Neutral |
| 2019-05-30 | Iniziato | ROTH Capital | Buy |
| 2019-05-23 | Iniziato | Stifel | Buy |
| 2019-01-23 | Iniziato | Mizuho | Buy |
| 2018-04-10 | Iniziato | JP Morgan | Overweight |
| 2018-03-16 | Iniziato | Guggenheim | Neutral |
| 2018-03-05 | Reiterato | Jefferies | Buy |
| 2018-02-28 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | Downgrade | Citigroup | Neutral → Sell |
| 2018-01-03 | Aggiornamento | Citigroup | Sell → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
Mostra tutto
Atara Biotherapeutics Inc Borsa (ATRA) Ultime notizie
What analysts say about Atara Biotherapeutics Inc. stockTurbocharged investment results - Jammu Links News
Is Atara Biotherapeutics Inc. a good long term investmentTriple-digit wealth increases - Autocar Professional
What drives Atara Biotherapeutics Inc. stock priceOutstanding capital appreciation - Jammu Links News
How Atara Biotherapeutics Inc. stock performs during market volatilityDaily Breakout Picks - Newser
Why Atara Biotherapeutics Inc. stock attracts strong analyst attentionFree Discussion Group - Newser
What makes Atara Biotherapeutics Inc. stock price move sharplyFree Consultation - Newser
Major FDA Development: Pierre Fabre Assumes Control of Atara's EBV Cell Therapy Program After BLA Resubmission - Stock Titan
Atara Biotherapeutics Resubmits BLA for Tab-cel to FDA - TipRanks
Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®) | ATRA Stock News - GuruFocus
Atara Biotherapeutics provides regulatory and business updates on tabelecleucel (tab-cel) - MarketScreener
Atara resubmits tabelecleucel BLA to FDA for EBV-positive PTLD By Investing.com - Investing.com Canada
Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel - Business Wire
(ATRA) Technical Data - news.stocktradersdaily.com
We Might See A Profit From Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Soon - simplywall.st
Atara Biotherapeutics, Inc.(NasdaqGS: ATRA) added to Russell Microcap Growth Index - MarketScreener
Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace
Atara Biotherapeutics Holds Annual Stockholders Meeting - TipRanks
Long Term Trading Analysis for (ATRA) - news.stocktradersdaily.com
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Northern Trust Corp Purchases New Position in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Defense World
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Short Interest Update - Defense World
Bank of America Corp DE Acquires 1,543 Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Defense World
Redmile Group, LLC's Strategic Acquisition in Atara Biotherapeutics Inc - GuruFocus
Here's Why You Should Consider Buying Atara Biotherapeutics Stock - Barchart.com
Biotech Pioneer Pascal Touchon Joins CDR-Life Board: Former Atara CEO to Drive T Cell Platform Innovation - Stock Titan
(ATRA) Trading Advice - news.stocktradersdaily.com
Atara Biotherapeutics (NASDAQ:ATRA) & Turnstone Biologics (NASDAQ:TSBX) Financial Analysis - Defense World
Top Executives at Atara Biotherapeutics Make Significant Stock Sales! - TipRanks
Atara Biotherapeutics Executives Sell Shares for Tax Obligations - TradingView
Citadel Advisors LLC Has $3.56 Million Position in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Defense World
FDA Delivers Blow to ImmunityBio - Los Angeles Business Journal
Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors - BioSpace
Atara Biotherapeutics (ATRA) Expands Board Following $16 Million Offering | ATRA Stock News - GuruFocus
Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors | ATRA Stock News - GuruFocus
Atara Biotherapeutics Reports Strong Q1 2025 Results - TipRanks
(ATRA) Investment Analysis and Advice - news.stocktradersdaily.com
Atara Biotherapeutics Announces $16M Stock Offering - TipRanks
Atara Biotherapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Atara Biotherapeutics: Q1 Earnings Snapshot - CT Insider
Atara Biotherapeutics sets stock and warrant offering prices By Investing.com - Investing.com India
Atara Biotherapeutics Inc Azioni (ATRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.59%
0.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):